866-997-4948(US-Canada Toll Free)

Crizotinib (Non Small Cell Lung Cancer)-Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Non Small Cell Lung Cancer

No. of Pages : 33 Pages

 

GlobalDatas pharmaceuticals report, Crizotinib (Non Small Cell Lung Cancer)-Analysis and Forecasts to 2020 provides Crizotinib sales forecasts for US. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Non-Small Cell Lung Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData\'s team of industry experts.

 

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

 

Scope

  • Therapy area profile including patient population for the US.
  • Analysis and review of Crizotinib including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Crizotinib including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2013-2020 for Crizotinib in each of the seven major markets

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Contents

 

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 4
2.1 NSCLC Market 4
2.2 Epidemiology 4
2.3 Etiology 6
2.3.1 Tobacco 6
2.3.2 Radon 6
2.3.3 Asbestos 6
2.3.4 Other Environmental Agents 7
2.4 GlobalData Pipeline Report Guidance 8


3 NSCLC Disease: Market Characterization 9
3.1 NSCLC Disease Market 9
3.2 NSCLC Disease Market Forecasts and CAGR 9
3.3 Drivers for the NSCLC Disease Market 10
3.3.1 High Incidence 10
3.3.2 High Mortality Rate 11
3.3.3 Increased Use of Chemotherapy in Early Stages of NSCLC 11
3.3.4 Emergence of Targeted Drugs and Maintenance Therapy 11
3.3.5 Promising Pipeline Drugs 11

 

4 Tumor-Node-Metastases (TNM) Classification of NSCLC 12


5 Crizotinib 15
5.1 Introduction 15
5.2 Mechanism of Action 15
5.3 Clinical Studies 15
5.4 Factors Affecting Sales of Crizotinib 16
5.4.1 NSCLC Market 16
5.4.2 Niche Market 16
5.4.3 High Efficacy 16
5.4.4 Oral Administration 16
5.5 Drug Risk Benefit Score 16
5.5.1 Efficacy 17
5.5.2 Safety 17
5.5.3 Compliance 17
5.5.4 Dosing Convenience 17
5.6 Intensity of Competition 17
5.7 Sales forecast 18
5.7.1 Target patient Pool of Crizotinib 18
5.7.2 Dosing 18
5.7.3 Market Penetration 19
5.7.4 Annual Cost of Therapy 19
5.7.5 Sales Projections of Crizotinib 20


6 NSCLC Market: Appendix 29
6.1 Market Definitions 29
6.2 Abberiviations 29
6.3 Research Methodology 29
6.3.1 Coverage 30
6.3.2 Secondary Research 30
6.3.3 Forecasting 30
6.3.4 Number of Patients Approved to take the Drug 31
6.3.5 Net Penetration of Drug 31
6.3.6 Net Annual Dosing 32
6.3.7 Annual Cost of Therapy 32
6.3.8 Primary Research 32
6.3.9 Expert Panels 32
6.4 Contact Us 33
6.5 Disclaimer 33
6.6 Sources 33

List of Table


Table 1: NSCLC, Incidences and Mortality, 20082030 5
Table 2: NSCLC, Global, Market Size Forecast ($bn), 20092020 9
Table 3: Drug Risk Benefit Score of Crizotinib 17
Table 4: Crizotinib, NSCLC, Global Sales Forecast ($m), 20132020 20
Table 5: Crizotinib, NSCLC, The US,Sales Forecast ($m), 20132020 21
Table 6: Crizotinib, NSCLC, The UK,Sales Forecast ($m), 20132020 22
Table 7: Crizotinib, NSCLC, France,Sales Forecast ($m), 20132020 23
Table 8: Crizotinib, NSCLC, Germany,Sales Forecast ($m), 20132020 24
Table 9: Crizotinib, NSCLC, Italy,Sales Forecast ($m), 20132020 25
Table 10: Crizotinib, NSCLC, Spain,Sales Forecast ($m), 20132020 26
Table 11: Crizotinib, NSCLC, Japan,Sales Forecast ($m), 20132020 27

List of Chart


Figure 1: Percentage Distribution of Top 20 Cancers 4
Figure 2: Difference of % Distribution of Incidence and Mortality of Top 20 Cancers 5
Figure 3: Percentage Distribution of Different Types of NSCLC according to Incidence, 2008 6
Figure 4: % Share of Risk Factors in Developed Countries 7
Figure 5: Per Capita Cigarette Consumption, The US, 1976-2006 7
Figure 6: NSCLC, Global, Market Size Forecast ($bn), 20092020 9
Figure 7: Oncology, Global, Incidence (in million), 2008-2030 10
Figure 8: NSCLC, Global, Incidence (in million), 2008-2030 10
Figure 9: Broad Classification of NSCLC 12
Figure 10: Detailed TNM Classification 13
Figure 11: Classification of NSCLC 14
Figure 12: Structure of Crizotinib 16
Figure 13: Drug Model Diagram of Crizotinib 19
Figure 14: Crizotinib, NSCLC, Global Sales Forecast ($m), 20132020 21
Figure 15: Crizotinib, NSCLC,The US, Sales Forecast ($m), 20132020 22
Figure 16: Crizotinib, NSCLC,The UK, Sales Forecast ($m), 20132020 23
Figure 17: Crizotinib, NSCLC,France, Sales Forecast ($m), 20132020 24
Figure 18: Crizotinib, NSCLC,Germany, Sales Forecast ($m), 20132020 25
Figure 19: Crizotinib, NSCLC ,Italy, Sales Forecast ($m), 20132020 26
Figure 20: Crizotinib, NSCLC,Spain, Sales Forecast ($m), 20132020 27
Figure 21: Crizotinib, NSCLC, Japan, Sales Forecast ($m), 20132020 28
Figure 22: Crizotinib, NSCLC, Sales Forecast by Country ($m), 2020 29
Figure 23: GlobalData Methodology 30
Figure 24: Drug Model Diagram 32
Figure 25: Patients Approved for the Drug 33

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *